The Molluscum Cream Your Dermatologist Prescribed Doesn't Beat Doing Nothing

 If your pediatrician looked at your child's skin, said the word "molluscum," and told you to wait it out, that advice can feel like being sent home empty-handed. It isn't. It's the best-supported answer modern dermatology has, and the reason has less to do with your doctor's confidence and more to do with what happens when researchers actually test the alternatives.

The cream that never beat placebo

Molluscum contagiosum is a pox-family virus that shows up as small, dome-shaped, painless bumps, usually in kids between one and fourteen years old. It's common: the CDC and NIH clinical literature put US incidence at roughly six million cases a year. For two decades, the default dermatology response to a persistent case was a prescription for topical imiquimod, a 5% cream.

In May 2017, the Cochrane Collaboration, the same research body responsible for some of medicine's most rigorously vetted systematic reviews, published its analysis of every controlled trial it could find on molluscum treatment: 22 trials, 1,650 participants. Its finding on imiquimod was unambiguous. Topical 5% imiquimod performed no better than an inactive vehicle cream on clinical cure (moderate-quality evidence) or short-term improvement (high-quality evidence). Application-site reactions, meanwhile, were more frequent with imiquimod than with the placebo it failed to beat.

There's a detail buried in that history that makes the twenty years of prescribing even stranger: imiquimod was never FDA-approved for molluscum contagiosum in the first place. Its approvals cover genital warts, actinic keratosis, and superficial basal cell carcinoma. Dermatologists prescribed it off-label because early, smaller studies looked promising.

The Cochrane review is what happens when someone finally pools all the data and checks. Imiquimod wasn't alone in failing that check. The same 22-trial review found cryotherapy, potassium hydroxide, benzoyl peroxide, salicylic acid, and homeopathic remedies all failed to clearly outperform placebo. Cochrane's own plain-language conclusion: natural resolution remains a strong way to handle the condition.

That reframes "watch and wait" entirely. It isn't a doctor with nothing to offer. It's a doctor accurately describing an evidence base where the alternatives don't hold up.

What the virus is actually doing while you wait

Molluscum contagiosum doesn't sit passively on the skin. It infects keratinocytes, the cells that make up the epidermis, and once inside, it does something clever: it encodes its own proteins specifically to block chemokine signaling at the infection site, suppressing the local inflammatory response that would normally flag the intruder. Your immune system gets told, in effect, that nothing is happening. NCBI's clinical reference on the condition describes this exact mechanism, and it's why a bump can sit dormant and undetected for months, sometimes up to six months, before the immune system finally clears it, if it clears it at all without help.

Why it spreads so fast once it starts

Scratching makes an existing case worse through a process called auto-inoculation: break one lesion, and the virus rides the fingernail or the skin contact to a new site, seeding a second bump from the first. That's the mechanism behind the pattern so many parents describe, one bump on a Tuesday becoming nine or ten by the following month, and it's also the most common way an infection moves from one sibling to another in the same household: shared bath towels, gym mats, pool toys, and ordinary skin-to-skin contact during play are all documented transmission routes.

Standard incubation runs two to six weeks from exposure to a visible bump, though documented cases run as long as six months, which is long enough that pinpointing exactly where a child picked it up is often impossible, and not worth the energy it takes to try. The practical version of this: covering active lesions when possible, not sharing towels or bathwater during an active outbreak, and keeping a child's nails short to reduce scratching are reasonable, low-effort steps. None of them are a treatment. They're damage control while the immune system does the actual work.

What actually changed in 2024

For the first time in the history of this condition, there is now an FDA-approved treatment built and tested specifically for it. Berdazimer gel, brand name Zelsuvmi, was approved on January 5, 2024. It's a nitric-oxide-releasing gel, applied once daily at home for up to 12 weeks, and nitric oxide has documented direct antiviral activity. Here's where the honest numbers matter more than the headline. The phase 3 trial that supported FDA approval enrolled 891 patients. The label's own clinical studies data show complete clearance at week 12 of 32.4% for berdazimer versus 19.7% for vehicle, a real, statistically meaningful edge, and also not remotely a guarantee. A separate analysis of trial completers, reported elsewhere in the literature, shows a larger apparent gap, 37% versus 20% at week 12 and 60% versus 46% at week 24, but that population excludes patients who didn't finish the trial, which tends to inflate the numbers.

The FDA label figure is the more conservative, more decision-relevant one. Either way: berdazimer works better than doing nothing, and doing nothing still works for a meaningful share of kids on its own, which is exactly why "watch and wait" was never actually the weaker option.

Why some kids can't shake it

This is the more interesting question, and it's where a 2025 study earns its place in the conversation. Researchers looked at 2,278 children with molluscum, 1,931 without eczema and 347 with concurrent atopic dermatitis, and found the eczema group needed significantly more treatment sessions to clear: 73.9% of the eczema-free group cleared in a single visit, versus 47.3% of the eczema group.

Notably, the study did not find a significant difference in how long the infection actually lasted between groups, only in how many visits it took to resolve, and the study's own authors describe the eczema-molluscum relationship as "controversial" rather than settled. That nuance matters if you're going to cite this study; the honest claim is narrower than "eczema means a longer infection." The mechanistic story underneath it is plausible regardless: eczema means a compromised skin barrier, and a compromised barrier is an easier door for a virus that specifically exploits inflammation signaling to hide.

A separate 2025 ultrastructural imaging study, using direct cellular-level visualization, has shown the virus spreading through disrupted skin barrier tissue, which gives the eczema connection a mechanism, not just a correlation. Traditional Chinese Medicine got to a version of this same idea a long time before modern dermatology had the tools to explain it. In TCM theory, the lung and large intestine are paired "metal element" organs, both functioning as detox pathways; when either is inflamed or underperforming, the skin, which the framework treats as a downstream release valve, is where the overflow shows up as rashes, acne, or lesions that won't clear.

A history of asthma, frequent colds, or chronic congestion points toward lung weakness in this model; a history of constipation, diarrhea, or food poisoning points toward gut imbalance. It's not a substitute for the Cochrane data above. It's a different lens pointed at the same stubborn cases, worth taking seriously precisely because it's now converging with what a modern pediatric dataset independently found: eczema and skin-virus persistence travel together.

There's a deeper historical thread here too, one that didn't make it into the recorded episode but is worth including for anyone chasing the full research trail: a 1987 placebo-controlled Japanese trial tested coix seed, a classical Chinese herb traditionally assigned to damp, stubborn skin conditions, against placebo in 192 molluscum patients. The topline effect was modest (61.5% versus 55.4% rated "remarkable useful or useful"), but the trial specifically flagged "distinct effectiveness" in patients with atopic dermatitis, the exact subgroup a study published thirty-eight years later would independently identify as needing more treatment. Two data points, four decades apart, one from a TCM framework and one from modern pediatric dermatology, landing on the same vulnerable population.

That's not a treatment recommendation; the trial is old, unreplicated, and was never tested head-to-head against berdazimer. Still, two independent data points landing on the same vulnerable population, four decades apart, is worth knowing about. What this actually means for a parent deciding what to do next If your child's molluscum is behaving typically, clearing over months rather than years, watchful waiting is the choice the actual evidence supports, not a doctor giving up on your kid. If it's been sticking around a long time, or spreading fast through the household, berdazimer is now a real, FDA-tested option with honest, modest numbers behind it, worth a direct conversation with a dermatologist about whether it fits your situation.

And if the bumps have been camped out for the better part of a year with no sign of clearing, the more useful question stops being "which cream should I try next" and becomes whether there's an underlying skin-barrier or immune-terrain issue, eczema chief among them, keeping the door open. That's a conversation worth having with a clinician who takes both the trial data and the terrain seriously.

This content is for educational purposes only and does not constitute medical advice. Consult your child's pediatrician before making treatment decisions.